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Sunlmary 
Peptides from donor major histocompatibility complex (MHC)  molecules were examined for 
their activation of allogeneically primed T cells. After immunization with either allogeneic spleen 
cells or a skin allograft, primed T cells proliferate in response to peptides derived from polymorphic 
regions of a  and B chains of dass II allo-MHC molecules. The results demonstrate that presentation 
of donor-MHC  peptides by host-derived antigen-presenting cells is a common event in vivo. 
Thus,  self-restricted  T  cell recognition  of processed alloantigens may play a critical  role in 
transplantation.  An in-depth understanding of this response may result in the development of 
additional molecular therapies to combat allograft rejection. 
D 
uring transplantation or aUograft rejection, determinants 
encoded within the MHC of the donor are recognized 
by T  lymphocytes of the recipient. This recognition results 
in a potent immunological reaction in which donor cells are 
rapidly and specifically killed, and the graft is destroyed (1, 
2). It is generally accepted that T cells recognize foreign an- 
tigens in the form of peptides presented in association with 
self-MHC molecules. However, the molecular basis for the 
recognition of the allogeneic target is still controversial. Three 
nonexclusive models for the target structure that is recog- 
nized by alloreactive T lymphocytes have been proposed: (a) 
alloreactive T cells recognize polymorphic motifs present on 
the intact allo-MHC molecule, regardless of peptides bound 
to them; (b) self- (recipient) or allo- (donor) derived peptides 
interact with the native aUo-MHC molecules to create a se- 
ries of new determinants recognized by T  cells; (c) the allo- 
MHC molecules are processed into peptides and presented 
by self-MHC molecules to specific T  cells (3, 4). In this re- 
port,  we provide evidence for the third alternative. 
Materials and Methods 
Peptides.  Peptides were synthesized in the Norris Cancer Center 
Microchemistry Laboratory (USC) with an automated peptide syn- 
thesizer (430A; Applied Biosystems Inc., Foster City, CA) using 
modified Merrifield chemistry.  These peptides were also used in 
the studies reported in reference 5. 
T Cell Proliferation.  B10.A (H-2'), BALB/c (H-2d), and SJL/J 
(H-2')  mice were obtained from The Jackson Laboratory  (Bar 
Harbor, ME) and bred at UCLA. BALB/c and SJL/J mice were 
immunized in the foot pads with 2  x  107 irradiated  sphnocytes 
in 25/~1, along with 25 #1 of CFA (Difco Laboratories, Detroit, 
MI) on the dorsal surface of the foot. Popliteal lymph node cells 
and splenocytes  were obtained 10 d later, and used in antigen-induced 
proliferation  assays. Cell suspensions were cultured in 0.2 ml of 
serum-flee HL-1 medium (Ventrex,  Portland,  ME),  containing 
2 mM glutamine in 96-weU plates for 4 d (5  x  10  s cells/well). 
Proliferation was assessed by the incorporation of I/~Ci [3H]thy- 
midine during the last 18 h of culture. 
Skin Grafts.  SJL/J and BALB/c mice were anesthetized,  and 
then engrafted on the left side of the back with back skin (1-cm 
disk) from B10.A mice, according to the technique described by 
Billingham and Medawar  (6). 
Results and Discussion 
The molecular identity of the target structure recognized 
by T cells during an in vivo aUoresponse leading to graft re- 
jection is obscure. To address this issue, BALB/c (H-2 d) and 
SJL/J  (H-2 ~)  mice were  primed with  B10.A  (A  k,  Ek)-ir - 
radiated splenocytes. Lymph node T cell proliferation was tested 
10 d later in response to peptides from polymorphic regions 
of the ot and B chains of the A k class II molecule. As shown 
in Fig. 1 A, three MHC class II peptides, A~1-18,  A~68-81, 
and A~1-16,  elicited strong and dose-dependent T  cell pro- 
liferation  in  SJL  mice while  two  peptides,  A~49-63  and 
A~58-71, were nonstimulatory. In contrast, in cultures from 
BALB/c mice primed with B10.A-irradiated splenocytes, only 
peptides A~1-16  and A~58-71 induced in vitro T  cell pro- 
liferative responses (Fig.  1 B).  It is of interest that two of 
these peptides, A~68-81 and A~58-71,  cannot bind to B10.A 
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Figure 1.  Recipient lymph node T cells proliferate to donor MHC Pep- 
tides after immunization with allogeneic cells. Results are expressed as 
counts per minute obtained with lymph node cells stimulated in vitro with 
MHC peptides. Each group represents three SJL/J (.4) and three BALB/c 
(B) mice tested individually. The positive control responses to purified pro- 
tein derivative ranged from  152,000 to 197,420 cpm. 
MHC molecules,  thereby eliminating their presentation by 
allogeneic  MHC (5).  Irrelevant A' peptides  corresponding 
to the same regions  of the Ia molecule were inactive (data 
not shown). Lymph node cells from nonimmunized BALB/c 
or SJL/J mice or from B10.A mice primed with B10.A syn- 
geneic irradiated splenocytes did not respond to any of the 
Ak-derived peptides  (data not shown). 
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Figure 2.  R~pient splenic T cells proliferate to donor MHC peptides 
during graft rejection. Results are expressed as counts per minute obtained 
with spleen cells stimulated in vitro with MHC Peptides. Each group 
represents two SJL/J (A) and two BALB/c (B) mice tested individually. 
To determine whether analogous  responsiveness to allo- 
MHC peptides is induced during allograft rejection, BALB/c 
and SJL mice were grafted with skin from B10.A animals. 
10 d after the transplantation,  splenocytes of the recipients 
were tested for in vitro proliferation to the A k peptides. As 
shown  in Fig.  2,  SJL/J mice responded  to A~1-18  while 
BALB/c mice responded to A~58-71, as was observed for im- 
munizations performed with Ak-expressing allogeneic cells. 
Table  1.  Immunization  with donor MHC Peptides Reveals  New  T  Cell Determinants 
Recall with MHC  peptides in vitro 
Priming with B10.A  No Peptide  A~1-18  A~49-63  A~68-81  A~1-16  A~58-71 
sj~/j 
Skin graft  5  -+  2  28  _+  8  7  _+  2  7  _+  2  9  _+  3  6  _+  1 
Spleen cells  24  _+  3  139  _+  10  28  _+  4  109  +  18  152  _+  21  33  +  6 
MHC  peptide  5  _+  3  82  _+  5  152  _+  10  133  _+  8  103  _+  10  7  _+  2 
BALB/c 
Skin graft  2  _+  1  2  +  1  2  _+  0.8  ND  3  _+  2  19  _+  2 
Spleen cells  19  +  2  25  _+  6  21  _+  6  ND  49  _+  9  53  _+  6 
MHC  peptide  4  _+  3  3  _+  1  2  _+  0.5  ND  52  +  5  89  _+  11 
Results are expressed as counts per minute. The values that are significantly over the background counts _+  SD are underlined. 
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T cell responses in SJL/J and BALB/c, respectively, after skin 
grafting, in contrast to splenocyte  injection. Spleen cells from 
normal untreated mice and from B10.A mice that received 
an autograft with B10.A skin did not proliferate in response 
to the same class II MHC peptides (data  not shown). 
Direct immunization of BALB/c and SJL mice with the 
Ak-derived peptides resulted in T  cell proliferation to the 
same determinants as after immunization with allogeneic cells. 
Moreover,  this approach revealed an additional determinant 
on the A k molecule that was undetected after immunization 
with allogeneic cells (Table 1). A~49-63 was clearly immu- 
nogenic in SJL mice but could not elicit  a T  cell response 
in mice primed with splenocytes or with a skin graft. This 
peptide can be considered to contain a nondominant or cryptic 
determinant that is not produced efficiently during processing. 
In this sense, MHC molecules are similar to other protein 
antigens (e.g., lysozyme) which contain both dominant and 
cryptic determinant regions (7). It is noteworthy that upon 
skin grafting, only one of the four, or one of the two, poten- 
tially immunogenic  peptides is presented in SJL/J and BALB/c, 
respectively; presumably, these are the most dominant deter- 
minants. This result indicates that the method of immuniza- 
tion influences the nature of the determinants recognized by 
T cells on a multideterminant antigen and suggests that during 
the process of skin graft rejection, because of less efficient 
processing, only the predominant determinants will be pre- 
sented to induce T  cell proliferation. 
The ability to recall responses with peptides in vitro after 
in vivo priming with intact cells or with skin grafting dearly 
indicates that donor MHC class II processing and peptide 
presentation occur during the course of an in vivo allogeneic 
response.  The proliferative responses to the two peptides 
A~68-81 and A~58-71, which failed to bind to donor A k or 
E  k MHC molecules, must have been presented by the recip- 
ient (H-2  ~  or H-2  a) MHC molecules. This demonstrates that 
one portion of the in vivo alloresponse to these alIo-MHC 
peptides is restricted to the MHC molecules of the recipient. 
In the case of A~1-16, we cannot exclude the possibility that 
this MHC class II peptide was presented in association with 
the donor-derived class II MHC molecules (8). However, this 
is unlikely since we have shown that this peptide is not effec- 
tively processed in situ and is not presented by A~-bearing 
APC of the donor (5). 
The molecular basis of allorecognition has been the sub- 
ject of intense investigation, especially the characterization 
of the target structures recognized by cloned T lymphocytes. 
In several instances,  CD4 + aUoreactive T lymphocytes play 
a crucial role in the alloresponse and have been shown to be 
sufficient for graft rejection (9, 10). One set of such studies 
on the topology of the target of alloreactive clones used single- 
site mutations to modify the reactivity of particular clones 
(4, 11, 12). It has been observed that amino acids located at 
a distance in the primary sequence could influence TCK rec- 
ognition and/or peptide binding only when they were mu- 
tated simultaneously, supporting a model in which alloreac- 
rive T lymphocytes recognize spatially distinct residues on 
the o~ and B chains of the intact allo-MHC molecule (4, 11, 
12). Alternatively, any modification of the structure of the 
allo-MHC target molecule could have also affected its pro- 
cessing and its hter presentation in the form ofMHC peptides. 
It has been recently reported that donor MHC class I-de- 
rived peptides, in association with class I molecules or class 
II molecules, can be recognized by aUoreactive cytotoxic cells 
(13-15)  or CD4 + alloreactive T  lymphocytes (16), respec- 
tively. Here we have shown that during in vivo alloresponses, 
determinants on foreign MHC molecules can be presented 
to T cells in the form of peptides associated with self-MHC 
molecules. Arnold et al. (17) recently showed that mice ex- 
pressing a class I  (K  k) transgene, although tolerant to al- 
logeneic MHC peptide fragments presented in association 
with self-MHC dass I molecules (Db), reacted at high fre- 
quency to the membrane form of the allo-MHC molecules. 
These results indicate that both membrane-bound  intact allo- 
MHC molecules and allo-MHC peptides presented in the con- 
text of a self-MHC restriction element are suitable  targets 
in allorecognition. 
How crucial is donor MHC peptide presentation by recip- 
ient MHC molecules in the actual rejection process, as com- 
pared with T cell responses directed against the intact donor 
MHC molecules? It is well established that after transplanta- 
tion, the passenger leukocytes of the donor (macrophages, 
Langerhans, and dendritic cells) leave the graft and can be 
found in the draining lymph nodes and spleen of the recip- 
ient (18). These bone marrow-derived, donor class II-posi- 
tive cells then prime recipient T cells that recognize the in- 
tact allogeneic MHC molecules present on their surface. After 
recognition of the native allo-antigen, primed T cells of the 
recipient can infiltrate the graft and secrete lymphokines. For 
example, IFN-3/induces further class II expression on epi- 
thelial cells of the graft (19). After the passenger leukocytes 
have left the graft, these epithelial cells should be the only 
allogeneic Ia-expressing cells in the transplant. Interestingly, 
such non-bone marrow-derived class II-bearing cells have 
been demonstrated to imprint nonresponsiveness on sensi- 
tized T cell clones rather than triggering alloreactive T cell 
responses (20, 21). We surmise that recognition of native allo- 
MHC molecules is only critical for initiation of the rejection 
but it cannot be the mechanism for maintaining the rejec- 
tion. Instead, host-derived macrophages and other class II-posi- 
rive inflammatory cells infiltrate the graft (18), process donor 
MHC molecules, and present these allo-MHC peptides in 
the context of self-MHC class II. This mechanism should 
eventuate in completing the rejection by providing help for 
the production of donor-directed antibodies. 
The results presented in this article demonstrate that donor 
class II-derived peptides can be presented by recipient MHC 
molecules, a process that may play a critical role in the rejec- 
tion of the allograft.  With respect to the therapy,  while at 
an early stage in the rejection process, antigen presentation 
by donor MHC class II molecules might be an effective target; 
at a later point, blocking of recipient MHC class II mole- 
cules with antibodies or peptides may be an important factor 
in preventing the rejection. 
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